The latest advances in kidney diseases and related disorders.
The 40th Annual Meeting of the American Society of Nephrology was held in San Francisco, California, U.S.A., October 31-November 5, 2007. This meeting offered the latest findings in basic and clinical nephrology science and was attended by more than 11,000 nephrologists and related scientists from around the world. Recent data on the results of new drugs for the treatment of renal anemia that are under development, such as the continuous erythropoietin receptor activator (CERA), Hematidetrade mark, or the orally active prolyl hydroxylase inhibitors (FG-2216, FG-4592) were presented. The effect of clopidogrel on arteriovenous fistula patency and suitability, and the effects of the use of high-flux membranes on mortality in incident hemodialysis patients were also shown. The renoprotective effects of high doses of candesartan in chronic kidney disease patients with proteinuria or the additional antiproteinuric effects of aliskiren on top of angiotensin AT(1) receptor antagonism in patients with diabetic nephropathy were demonstrated. Recent studies that evaluated the efficacy and safety of new immunosuppressive strategies without calcineurin inhibitors in renal transplant recipients were also reviewed during the congress.
Cases
Aleix
A
Dialysis Section, Nephrology Department, Hospital Clinic i Provincial, Barcelona, Spain. acases@clinic.ub.es
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000628:therapy*; D016030:Kidney Transplantation; D006435:Renal Dialysis / Q000379:methods*